Reviva Pharmaceuticals Reports Q3 2026 Results and Outlook

What Happened

• Reviva Pharmaceuticals Holdings, Inc. (RVPH) filed a Form 8‑K (Item 2.02) on August 12, 2026 to disclose financial information and operating metrics for its fiscal quarter ended June 30, 2026 and to discuss its business outlook. The company issued a press release dated August 12, 2026 that is attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: August 12, 2026 (Form 8‑K, Item 2.02 — Results of Operations and Financial Condition).
• Period covered: fiscal quarter ended June 30, 2026.
• Press release containing the reported quarterly results and operating metrics is furnished as Exhibit 99.1.
• The 8‑K was furnished to the SEC; the press release provides the detailed earnings, revenue, and operating metrics.

Why It Matters

• This filing signals that Reviva has released its latest quarterly results and management’s view of near‑term performance—information investors use to evaluate earnings, revenue trends, and operational progress.
• The 8‑K itself summarizes that results and outlook were disclosed but does not include the detailed figures in the body of the filing; investors should review the attached press release (Exhibit 99.1) for specific revenue, earnings, and operating-metric figures to assess impacts on valuation or near‑term expectations.